Our studies within a single good-risk genotype, the t(8;21) subgroup, suggest that EZH2 mutation is an independent poor-risk characteristic in AML; however, further studies are necessary to determine its exact role as a prognostic factor. Here, EZH2 is linked to acute myeloid leukemia.